Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions
LGND Stock Forecast
Ligand Pharmaceuticals stock forecast is as follows: an average price target of $130.40 (represents a 16.64% upside from LGND’s last price of $111.80) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
LGND Price Target
The average price target for Ligand Pharmaceuticals (LGND) is $130.40 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $157.00 to $90.00. This represents a potential 16.64% upside from LGND's last price of $111.80.
LGND Analyst Ratings
According to 6 Wall Street analysts, Ligand Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LGND stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ligand Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Joseph Pantginis | H.C. Wainwright | $157.00 | $108.31 | 44.95% | 40.43% |
| Oct 02, 2024 | Leland Gershell | Oppenheimer | $135.00 | $99.95 | 35.07% | 20.75% |
| Jul 30, 2024 | Douglas Miehm | RBC Capital | $130.00 | $108.75 | 19.54% | 16.28% |
| Jul 09, 2024 | Matt Hewitt | Craig-Hallum | $140.00 | $86.88 | 61.14% | 25.22% |
| Jun 28, 2024 | Joseph Pantginis | H.C. Wainwright | $144.00 | $82.33 | 74.91% | 28.80% |
| Dec 23, 2022 | - | Roth Capital | $90.00 | $67.32 | 33.69% | -19.50% |
The latest Ligand Pharmaceuticals stock forecast, released on Oct 21, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $157.00, which represents a 44.95% increase from the stock price at the time of the forecast ($108.31), and a 40.43% increase from LGND last price ($111.80).
Ligand Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $157.00 | $146.00 | $141.20 |
| Last Closing Price | $111.80 | $111.80 | $111.80 |
| Upside/Downside | 40.43% | 30.59% | 26.30% |
In the current month, the average price target of Ligand Pharmaceuticals stock is $157.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 40.43% increase as opposed to Ligand Pharmaceuticals's last price of $111.80. This month's average price target is up 7.53% compared to last quarter, and up 11.19% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 03, 2024 | RBC Capital | Buy | Buy | Hold |
| Oct 03, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Oct 02, 2024 | Oppenheimer | - | Outperform | Initialise |
| Aug 12, 2024 | Benchmark | Buy | Buy | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 30, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 30, 2024 | RBC Capital | - | Outperform | Initialise |
| Jul 09, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Ligand Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 18, 2024. The company gave LGND a "Buy" rating, the same as its previous rate.
Ligand Pharmaceuticals Financial Forecast
Ligand Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $28.10M | $32.87M | $26.37M | $43.98M | $50.38M | $66.09M | $57.42M | $45.69M | $72.47M | $64.83M | $84.67M | $55.15M | $69.99M | $41.85M | $41.42M | $33.16M | $27.00M | $24.81M | $24.99M | $43.48M | $56.16M | $29.27M |
| Avg Forecast | $52.70M | $46.35M | $41.30M | $35.65M | $39.02M | $40.60M | $33.04M | $27.92M | $25.64M | $27.22M | $24.74M | $33.55M | $44.09M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $46.74M | $32.35M |
| High Forecast | $55.77M | $49.05M | $43.70M | $37.38M | $40.45M | $41.41M | $33.04M | $27.92M | $25.92M | $28.81M | $26.18M | $35.50M | $46.66M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $56.09M | $38.82M |
| Low Forecast | $49.07M | $43.16M | $38.45M | $33.91M | $36.17M | $39.78M | $33.04M | $27.92M | $25.37M | $25.35M | $23.03M | $31.24M | $41.05M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $37.39M | $25.88M |
| # Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 1.21% | 1.07% | 1.31% | 1.14% | 1.72% | 1.52% | 1.34% | 1.11% | 1.10% | 1.19% | 0.88% | 1.23% | 0.93% | 1.38% | 1.25% | 1.08% | 1.11% | 1.19% | 1.14% | 1.20% | 0.90% |
Ligand Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $27.92M, with a low forecast of $27.92M, and a high forecast of $27.92M. LGND's average Quarter revenue forecast represents a -0.63% decrease compared to the company's last Quarter revenue of $28.10M (Dec 23).
Ligand Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $-3.36M | $23.46M | $2.56M | $-16.79M | $-55.81M | $13.38M | $13.26M | $5.21M | $21.17M | $30.37M | $64.38M | $3.44M | $-11.07M | $7.40M | $12.78M | $7.32M | $-12.36M | $-1.61M | $-625.00K | $-795.55M | $41.28M | $13.34M |
| Avg Forecast | $23.39M | $20.57M | $18.33M | $15.82M | $17.31M | $18.02M | $14.66M | $6.03M | $11.38M | $12.08M | $10.98M | $5.48M | $7.03M | $223.10K | $219.68K | $4.33M | $378.92K | $341.95K | $415.70K | $18.57M | $329.95K | $262.48K | $174.40K | $-10.09M | $144.98K | $130.19K | $122.33K | $222.85K | $46.56M | $10.05M |
| High Forecast | $24.75M | $21.77M | $19.39M | $16.59M | $17.95M | $18.37M | $14.66M | $7.24M | $11.50M | $12.78M | $11.62M | $6.58M | $8.44M | $223.10K | $219.68K | $5.20M | $378.92K | $341.95K | $415.70K | $22.28M | $329.95K | $262.48K | $174.40K | $-8.07M | $144.98K | $130.19K | $122.33K | $222.85K | $55.87M | $12.05M |
| Low Forecast | $21.78M | $19.15M | $17.06M | $15.05M | $16.05M | $17.66M | $14.66M | $4.82M | $11.26M | $11.25M | $10.22M | $4.39M | $5.62M | $223.10K | $219.68K | $3.47M | $378.92K | $341.95K | $415.70K | $14.86M | $329.95K | $262.48K | $174.40K | $-12.11M | $144.98K | $130.19K | $122.33K | $222.85K | $37.25M | $8.04M |
| Surprise % | - | - | - | - | - | - | - | - | -0.30% | 1.94% | 0.23% | -3.06% | -7.94% | 59.96% | 60.38% | 1.20% | 55.86% | 88.83% | 154.88% | 0.19% | -33.55% | 28.20% | 73.27% | -0.73% | -85.22% | -12.34% | -5.11% | -3569.88% | 0.89% | 1.33% |
3 analysts predict LGND's average Quarter EBITDA for Dec 23 to be $11.38M, with a high of $11.50M and a low of $11.26M. This is -51.49% lower than Ligand Pharmaceuticals's previous annual EBITDA (Sep 23) of $23.46M.
Ligand Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $18.19M | $-12.79M | $2.29M | $41.95M | $-14.53M | $404.00K | $-895.00K | $-15.38M | $-4.97M | $13.72M | $30.73M | $18.11M | $5.76M | $-6.70M | $22.09M | $-24.13M | $-7.37M | $-15.25M | $-14.42M | $666.34M | $45.28M | $5.08M |
| Avg Forecast | $33.22M | $29.73M | $25.21M | $22.53M | $21.76M | $24.81M | $19.45M | $-24.00M | $12.17M | $11.42M | $11.71M | $-21.82M | $-3.38M | $5.03M | $5.00M | $-17.25M | $15.94M | $12.30M | $16.07M | $13.62M | $12.68M | $11.42M | $8.84M | $-15.72M | $7.47M | $7.10M | $6.40M | $574.88M | $36.15M | $5.56M |
| High Forecast | $35.73M | $31.98M | $27.12M | $24.24M | $27.27M | $24.86M | $19.46M | $-19.20M | $13.09M | $12.28M | $12.60M | $-17.46M | $-2.70M | $5.03M | $5.00M | $-13.80M | $15.94M | $12.30M | $16.07M | $16.34M | $12.68M | $11.42M | $8.84M | $-12.58M | $7.47M | $7.10M | $6.40M | $689.85M | $43.38M | $6.68M |
| Low Forecast | $30.24M | $27.07M | $22.95M | $20.51M | $14.42M | $24.77M | $19.45M | $-28.80M | $11.08M | $10.40M | $10.67M | $-26.19M | $-4.06M | $5.03M | $5.00M | $-20.70M | $15.94M | $12.30M | $16.07M | $10.90M | $12.68M | $11.42M | $8.84M | $-18.87M | $7.47M | $7.10M | $6.40M | $459.90M | $28.92M | $4.45M |
| Surprise % | - | - | - | - | - | - | - | - | 1.49% | -1.12% | 0.20% | -1.92% | 4.30% | 0.08% | -0.18% | 0.89% | -0.31% | 1.12% | 1.91% | 1.33% | 0.45% | -0.59% | 2.50% | 1.53% | -0.99% | -2.15% | -2.25% | 1.16% | 1.25% | 0.91% |
Ligand Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-24.00M, with a range of $-28.80M to $-19.20M. LGND's average Quarter net income forecast represents a -231.97% decrease compared to the company's last Quarter net income of $18.19M (Dec 23).
Ligand Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $15.99M | $14.66M | $11.29M | $10.86M | $31.13M | $17.45M | $14.59M | $18.18M | $17.74M | $12.72M | $14.71M | $12.62M | $30.08M | $15.02M | $10.07M | $9.26M | $10.28M | $9.53M | $10.99M | $11.09M | $7.64M | $7.32M |
| Avg Forecast | $17.50M | $15.39M | $13.71M | $11.84M | $12.96M | $13.48M | $10.97M | $9.27M | $8.52M | $9.04M | $8.21M | $25.79M | $12.07M | $12.73M | $12.53M | $20.38M | $21.61M | $19.50M | $23.71M | $9.49M | $18.82M | $14.97M | $9.95M | $6.04M | $8.27M | $7.43M | $6.98M | $9.57M | $6.10M | $8.02M |
| High Forecast | $18.52M | $16.29M | $14.51M | $12.41M | $13.43M | $13.75M | $10.97M | $9.27M | $8.61M | $9.57M | $8.69M | $30.94M | $14.48M | $12.73M | $12.53M | $24.46M | $21.61M | $19.50M | $23.71M | $11.39M | $18.82M | $14.97M | $9.95M | $7.24M | $8.27M | $7.43M | $6.98M | $11.48M | $7.32M | $9.62M |
| Low Forecast | $16.29M | $14.33M | $12.77M | $11.26M | $12.01M | $13.21M | $10.97M | $9.27M | $8.43M | $8.42M | $7.65M | $20.63M | $9.65M | $12.73M | $12.53M | $16.31M | $21.61M | $19.50M | $23.71M | $7.59M | $18.82M | $14.97M | $9.95M | $4.83M | $8.27M | $7.43M | $6.98M | $7.65M | $4.88M | $6.42M |
| Surprise % | - | - | - | - | - | - | - | - | 1.88% | 1.62% | 1.37% | 0.42% | 2.58% | 1.37% | 1.16% | 0.89% | 0.82% | 0.65% | 0.62% | 1.33% | 1.60% | 1.00% | 1.01% | 1.53% | 1.24% | 1.28% | 1.58% | 1.16% | 1.25% | 0.91% |
Ligand Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $9.27M, based on 1 Wall Street analysts, with a range of $9.27M to $9.27M. The forecast indicates a -42.02% fall compared to LGND last annual SG&A of $15.99M (Dec 23).
Ligand Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| EPS | - | - | - | - | - | - | - | - | $1.03 | $-0.74 | $0.13 | $2.46 | $-0.86 | $0.02 | $-0.05 | $-0.91 | $-0.30 | $0.82 | $1.84 | $1.10 | $0.36 | $-0.42 | $1.38 | $-1.46 | $-0.43 | $-0.81 | $-0.74 | $32.59 | $2.13 | $0.24 |
| Avg Forecast | $1.80 | $1.61 | $1.37 | $1.22 | $1.18 | $1.35 | $1.06 | $0.83 | $0.66 | $0.62 | $0.64 | $0.89 | $0.77 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $1.03 | $0.69 |
| High Forecast | $1.94 | $1.74 | $1.47 | $1.32 | $1.48 | $1.35 | $1.06 | $0.90 | $0.71 | $0.67 | $0.68 | $0.96 | $0.83 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $1.24 | $0.83 |
| Low Forecast | $1.64 | $1.47 | $1.25 | $1.11 | $0.78 | $1.34 | $1.06 | $0.76 | $0.60 | $0.56 | $0.58 | $0.81 | $0.70 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $0.82 | $0.55 |
| Surprise % | - | - | - | - | - | - | - | - | 1.56% | -1.19% | 0.20% | 2.75% | -1.11% | 0.07% | -0.19% | -2.15% | -0.34% | 1.20% | 2.06% | 1.52% | 0.51% | -0.66% | 2.81% | -3.45% | -1.04% | -2.06% | -2.09% | 1.69% | 2.07% | 0.35% |
According to 1 Wall Street analysts, Ligand Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.83, with a low estimate of $0.76 and a high estimate of $0.90. This represents a -19.03% decrease compared to LGND previous annual EPS of $1.03 (Dec 23).
Ligand Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.48 | $6.00 | 1150.00% | Buy |
| LYEL | Lyell Immunopharma | $1.11 | $6.67 | 500.90% | Hold |
| RLAY | Relay Therapeutics | $4.80 | $19.40 | 304.17% | Buy |
| GPCR | Structure Therapeutics | $32.78 | $92.40 | 181.88% | Buy |
| ETNB | 89bio | $7.99 | $22.00 | 175.34% | Buy |
| APLS | Apellis Pharmaceuticals | $28.99 | $74.50 | 156.99% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| CGEM | Cullinan Oncology | $13.10 | $31.50 | 140.46% | Buy |
| RCUS | Arcus Biosciences | $14.51 | $33.00 | 127.43% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.89 | $17.00 | 91.23% | Buy |
| VRDN | Viridian Therapeutics | $20.24 | $37.92 | 87.35% | Buy |
| DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| ASND | Ascendis Pharma | $124.44 | $190.21 | 52.85% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| BGNE | BeiGene | $187.77 | $255.80 | 36.23% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.17 | $70.14 | 27.13% | Buy |
| LGND | Ligand Pharmaceuticals | $111.80 | $130.40 | 16.64% | Buy |
| BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |